comparemela.com

Latest Breaking News On - Revance therapeutics company profile - Page 2 : comparemela.com

Revance Therapeutics, Inc (NASDAQ:RVNC) Given Consensus Recommendation of Moderate Buy by Brokerages

Revance Therapeutics, Inc (NASDAQ:RVNC) Given Consensus Recommendation of Moderate Buy by Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Revance Therapeutics (NASDAQ:RVNC) Trading Down 3 8%

Revance Therapeutics (NASDAQ:RVNC) Trading Down 3 8%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Revance Therapeutics, Inc (NASDAQ:RVNC) Shares Purchased by Innovis Asset Management LLC

Innovis Asset Management LLC lifted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 266.1% in the third quarter, HoldingsChannel reports. The firm owned 38,501 shares of the biopharmaceutical company’s stock after purchasing an additional 27,984 shares during the period. Innovis Asset Management LLC’s holdings in Revance Therapeutics were worth $442,000 at the […]

Revance Therapeutics (NASDAQ:RVNC) Stock Price Up 12 5%

Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) shares shot up 12.5% during mid-day trading on Tuesday . The company traded as high as $5.81 and last traded at $5.74. 615,845 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 1,640,345 shares. The stock had previously closed at […]

Revance Therapeutics (NASDAQ:RVNC) Stock Price Up 12 5%

Revance Therapeutics (NASDAQ:RVNC) Stock Price Up 12 5%
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.